Molika Ashford

The data, while limited, indicate that the firm's blood-only assay may be able to match the performance of existing commercial tissue-informed competitors.

The firm continues to pursue new applications for its multiomics machine learning technology, with recent data exploring immunotherapy response prediction.

More than 45 centers are collaborating to uncover germline contributions to immunotherapy response and resistance and bring polygenic predictors to the clinic.

Recent results from the firm's case-control study cohort showed overall sensitivity of about 50 percent but higher performance for a subset of high-mortality cancers.

The firm presented evidence that its DetermaIO gene expression test can help predict which bladder cancer patients are likely to respond to immune checkpoint inhibitors.

The company has previously offered its liquid biopsy tests through an LDT model but sees the timing and the clinical niche as right for a regulatory bid in CSF testing.

If the team is successful in expanding on the results that they reported last month, it could open a new application for the still nascent circulating tumor DNA technology.

The results represent a significant improvement over currently used screening tools and are spurring renewed LDT commercialization and regulatory submission efforts.

The company plans to transition its DetermaIO test from research to clinical use and to launch a new research product for immunotherapy monitoring by the end of this year.

The firm highlighted a new study exploring immune-related gene expression in ovarian cancer and gave an update on its lead diagnostic candidate for head and neck tumors.